PittsburghV1, Main, Exploration, bibRecord, 005113

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Identifieur interne : 005113 ( Main/Exploration ); précédent : 005112; suivant : 005114

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Auteurs : Patrick J. Schuler [États-Unis, Allemagne] ; Malgorzata Harasymczuk [États-Unis] ; Carmen Visus [États-Unis] ; Albert Deleo [États-Unis] ; Sumita Trivedi [États-Unis] ; YU LEI [États-Unis] ; Athanassios Argiris [États-Unis] ; William Gooding [États-Unis] ; Lisa H. Butterfield [États-Unis] ; Theresa L. Whiteside [États-Unis] ; Robert L. Ferris [États-Unis]

Source :

Clinical cancer research : (Print) [ 1078-0432 ] ; 2014.

RBID : Pascal:14-0132168

Descripteurs français

KwdFr :
- Adulte, Adulte d'âge moyen, Carcinome épidermoïde (), Carcinome épidermoïde (anatomopathologie), Carcinome épidermoïde (génétique), Carcinome épidermoïde (immunologie), Carcinome épidermoïde (mortalité), Cellules dendritiques (immunologie), Cellules dendritiques (métabolisme), Cytokines (biosynthèse), Fragments peptidiques (immunologie), Humains, Immunophénotypage, Immunothérapie (effets indésirables), Lymphocytes T cytotoxiques (immunologie), Lymphocytes T cytotoxiques (métabolisme), Lymphocytes T régulateurs (immunologie), Lymphocytes T régulateurs (métabolisme), Lymphocytes TIL (immunologie), Lymphocytes TIL (métabolisme), Phénotype, Protéine p53 suppresseur de tumeur (), Protéine p53 suppresseur de tumeur (immunologie), Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Tumeurs de la tête et du cou (), Tumeurs de la tête et du cou (anatomopathologie), Tumeurs de la tête et du cou (génétique), Tumeurs de la tête et du cou (immunologie), Tumeurs de la tête et du cou (mortalité), Vaccination, Vaccins anticancéreux (administration et posologie), Vaccins anticancéreux (effets indésirables), Vaccins anticancéreux (immunologie).
MESH :
- administration et posologie : Vaccins anticancéreux.
- anatomopathologie : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- biosynthèse : Cytokines.
- effets indésirables : Immunothérapie, Vaccins anticancéreux.
- génétique : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- immunologie : Carcinome épidermoïde, Cellules dendritiques, Fragments peptidiques, Lymphocytes T cytotoxiques, Lymphocytes T régulateurs, Lymphocytes TIL, Protéine p53 suppresseur de tumeur, Tumeurs de la tête et du cou, Vaccins anticancéreux.
- mortalité : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- métabolisme : Cellules dendritiques, Lymphocytes T cytotoxiques, Lymphocytes T régulateurs, Lymphocytes TIL.
Pascal (Inist)
- Adulte, Adulte d'âge moyen, Carcinome épidermoïde, Cellule dendritique, Cellule APC, Gène TP53, Gène suppresseur tumeur, Cancer de la tête et du cou, Gène p53, Humains, Immunophénotypage, Phénotype, Protéine p53 suppresseur de tumeur, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Tumeurs de la tête et du cou, Vaccin peptidique, Vaccination.

English descriptors

KwdEn :
- Adult, Aged, Antigen presenting cell, Cancer Vaccines (administration & dosage), Cancer Vaccines (adverse effects), Cancer Vaccines (immunology), Carcinoma, Squamous Cell (genetics), Carcinoma, Squamous Cell (immunology), Carcinoma, Squamous Cell (mortality), Carcinoma, Squamous Cell (pathology), Carcinoma, Squamous Cell (therapy), Cytokines (biosynthesis), Dendritic Cells (immunology), Dendritic Cells (metabolism), Dendritic cell, Head and Neck Neoplasms (genetics), Head and Neck Neoplasms (immunology), Head and Neck Neoplasms (mortality), Head and Neck Neoplasms (pathology), Head and Neck Neoplasms (therapy), Head and neck cancer, Humans, Immunophenotyping, Immunotherapy (adverse effects), Lymphocytes, Tumor-Infiltrating (immunology), Lymphocytes, Tumor-Infiltrating (metabolism), Middle Aged, Neoplasm Staging, Peptide Fragments (immunology), Peptide vaccine, Phenotype, T-Lymphocytes, Cytotoxic (immunology), T-Lymphocytes, Cytotoxic (metabolism), T-Lymphocytes, Regulatory (immunology), T-Lymphocytes, Regulatory (metabolism), TP53 Gene, Treatment Outcome, Tumor Suppressor Protein p53 (chemistry), Tumor Suppressor Protein p53 (immunology), Tumor suppressor gene, Vaccination.
MESH :
- chemical , administration & dosage : Cancer Vaccines.
- chemical , adverse effects : Cancer Vaccines.
- chemical , biosynthesis : Cytokines.
- chemical , chemistry : Tumor Suppressor Protein p53.
- chemical , immunology : Cancer Vaccines, Peptide Fragments, Tumor Suppressor Protein p53.
- adverse effects : Immunotherapy.
- genetics : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- immunology : Carcinoma, Squamous Cell, Dendritic Cells, Head and Neck Neoplasms, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Cytotoxic, T-Lymphocytes, Regulatory.
- metabolism : Dendritic Cells, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Cytotoxic, T-Lymphocytes, Regulatory.
- mortality : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- pathology : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- Adult, Aged, Humans, Immunophenotyping, Middle Aged, Neoplasm Staging, Phenotype, Treatment Outcome, Vaccination.

Abstract

Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against p53 was tested in a phase I clinical trial. Experimental Methods: Monocyte-derived DC from 16 patients were loaded with two modified HLA-class I p53 peptides (Arm 1), additional Th tetanus toxoid peptide (Arm 2), or additional Th wild-type (wt) p53-specific peptide (Arm 3). Vaccine DCs (vDC) were delivered to inguinal lymph nodes at three time points. vDC phenotype, circulating p53-specific T cells, and regulatory T cells (Treg) were serially monitored by flow cytometry and cytokine production by Luminex. vDC properties were compared with those of DC1 generated with an alternative maturation regimen. Results: No grade II-IV adverse events were observed. Two-year disease-free survival of 88% was favorable. p53-specific T-cell frequencies were increased postvaccination in 11 of 16 patients (69%), with IFN-y secretion detected in four of 16 patients. Treg frequencies were consistently decreased (P = 0.006) relative to prevaccination values. The phenotype and function of DC1 were improved relative to vDC. Conclusion: Adjuvant p53-specific vaccination of patients with HNSCC was safe and associated with promising clinical outcome, decreased Treg levels, and modest vaccine-specific immunity. HNSCC patients' DC required stronger maturation stimuli to reverse immune suppression and improve vaccine efficacy.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017234

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer</title>
<author><name sortKey="Schuler, Patrick J" sort="Schuler, Patrick J" uniqKey="Schuler P" first="Patrick J." last="Schuler">Patrick J. Schuler</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Department of Otolaryngology, University of Ulm</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><settlement type="city">Ulm</settlement>
<region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="Harasymczuk, Malgorzata" sort="Harasymczuk, Malgorzata" uniqKey="Harasymczuk M" first="Malgorzata" last="Harasymczuk">Malgorzata Harasymczuk</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Visus, Carmen" sort="Visus, Carmen" uniqKey="Visus C" first="Carmen" last="Visus">Carmen Visus</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pathology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deleo, Albert" sort="Deleo, Albert" uniqKey="Deleo A" first="Albert" last="Deleo">Albert Deleo</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pathology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trivedi, Sumita" sort="Trivedi, Sumita" uniqKey="Trivedi S" first="Sumita" last="Trivedi">Sumita Trivedi</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu Lei" sort="Yu Lei" uniqKey="Yu Lei" last="Yu Lei">YU LEI</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Argiris, Athanassios" sort="Argiris, Athanassios" uniqKey="Argiris A" first="Athanassios" last="Argiris">Athanassios Argiris</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Medicine, Hematology/Oncology, University of Texas-San Antonio Cancer Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gooding, William" sort="Gooding, William" uniqKey="Gooding W" first="William" last="Gooding">William Gooding</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Biostatistics Facility, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Butterfield, Lisa H" sort="Butterfield, Lisa H" uniqKey="Butterfield L" first="Lisa H." last="Butterfield">Lisa H. Butterfield</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0132168</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0132168 INIST</idno>
<idno type="RBID">Pascal:14-0132168</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B25</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003B03</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000460</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000460</idno>
<idno type="wicri:doubleKey">1078-0432:2014:Schuler P:phase:i:dendritic</idno>
<idno type="wicri:Area/Main/Merge">005383</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017234</idno>
<idno type="RBID">PMC:4017234</idno>
<idno type="wicri:Area/Pmc/Corpus">001907</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001907</idno>
<idno type="wicri:Area/Pmc/Curation">001882</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001882</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000999</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000999</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002E19</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E19</idno>
<idno type="wicri:Area/PubMed/Curation">002E00</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E00</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E00</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E00</idno>
<idno type="wicri:Area/Ncbi/Merge">001346</idno>
<idno type="wicri:Area/Ncbi/Curation">001346</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001346</idno>
<idno type="wicri:doubleKey">1078-0432:2014:Schuler P:phase:i:dendritic</idno>
<idno type="wicri:Area/Main/Merge">001C14</idno>
<idno type="wicri:Area/Main/Curation">005113</idno>
<idno type="wicri:Area/Main/Exploration">005113</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer</title>
<author><name sortKey="Schuler, Patrick J" sort="Schuler, Patrick J" uniqKey="Schuler P" first="Patrick J." last="Schuler">Patrick J. Schuler</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Department of Otolaryngology, University of Ulm</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><settlement type="city">Ulm</settlement>
<region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author><name sortKey="Harasymczuk, Malgorzata" sort="Harasymczuk, Malgorzata" uniqKey="Harasymczuk M" first="Malgorzata" last="Harasymczuk">Malgorzata Harasymczuk</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Visus, Carmen" sort="Visus, Carmen" uniqKey="Visus C" first="Carmen" last="Visus">Carmen Visus</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pathology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deleo, Albert" sort="Deleo, Albert" uniqKey="Deleo A" first="Albert" last="Deleo">Albert Deleo</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pathology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trivedi, Sumita" sort="Trivedi, Sumita" uniqKey="Trivedi S" first="Sumita" last="Trivedi">Sumita Trivedi</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yu Lei" sort="Yu Lei" uniqKey="Yu Lei" last="Yu Lei">YU LEI</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Argiris, Athanassios" sort="Argiris, Athanassios" uniqKey="Argiris A" first="Athanassios" last="Argiris">Athanassios Argiris</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Medicine, Hematology/Oncology, University of Texas-San Antonio Cancer Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gooding, William" sort="Gooding, William" uniqKey="Gooding W" first="William" last="Gooding">William Gooding</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Biostatistics Facility, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Butterfield, Lisa H" sort="Butterfield, Lisa H" uniqKey="Butterfield L" first="Lisa H." last="Butterfield">Lisa H. Butterfield</name>
<affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Cancer Immunology Program, University of Pittsburgh Cancer Institute</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Otolaryngology, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, Pennsylvania</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical cancer research : (Print)</title>
<title level="j" type="abbreviated">Clin. cancer res. : (Print)</title>
<idno type="ISSN">1078-0432</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical cancer research : (Print)</title>
<title level="j" type="abbreviated">Clin. cancer res. : (Print)</title>
<idno type="ISSN">1078-0432</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Antigen presenting cell</term>
<term>Cancer Vaccines (administration & dosage)</term>
<term>Cancer Vaccines (adverse effects)</term>
<term>Cancer Vaccines (immunology)</term>
<term>Carcinoma, Squamous Cell (genetics)</term>
<term>Carcinoma, Squamous Cell (immunology)</term>
<term>Carcinoma, Squamous Cell (mortality)</term>
<term>Carcinoma, Squamous Cell (pathology)</term>
<term>Carcinoma, Squamous Cell (therapy)</term>
<term>Cytokines (biosynthesis)</term>
<term>Dendritic Cells (immunology)</term>
<term>Dendritic Cells (metabolism)</term>
<term>Dendritic cell</term>
<term>Head and Neck Neoplasms (genetics)</term>
<term>Head and Neck Neoplasms (immunology)</term>
<term>Head and Neck Neoplasms (mortality)</term>
<term>Head and Neck Neoplasms (pathology)</term>
<term>Head and Neck Neoplasms (therapy)</term>
<term>Head and neck cancer</term>
<term>Humans</term>
<term>Immunophenotyping</term>
<term>Immunotherapy (adverse effects)</term>
<term>Lymphocytes, Tumor-Infiltrating (immunology)</term>
<term>Lymphocytes, Tumor-Infiltrating (metabolism)</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Peptide Fragments (immunology)</term>
<term>Peptide vaccine</term>
<term>Phenotype</term>
<term>T-Lymphocytes, Cytotoxic (immunology)</term>
<term>T-Lymphocytes, Cytotoxic (metabolism)</term>
<term>T-Lymphocytes, Regulatory (immunology)</term>
<term>T-Lymphocytes, Regulatory (metabolism)</term>
<term>TP53 Gene</term>
<term>Treatment Outcome</term>
<term>Tumor Suppressor Protein p53 (chemistry)</term>
<term>Tumor Suppressor Protein p53 (immunology)</term>
<term>Tumor suppressor gene</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Carcinome épidermoïde ()</term>
<term>Carcinome épidermoïde (anatomopathologie)</term>
<term>Carcinome épidermoïde (génétique)</term>
<term>Carcinome épidermoïde (immunologie)</term>
<term>Carcinome épidermoïde (mortalité)</term>
<term>Cellules dendritiques (immunologie)</term>
<term>Cellules dendritiques (métabolisme)</term>
<term>Cytokines (biosynthèse)</term>
<term>Fragments peptidiques (immunologie)</term>
<term>Humains</term>
<term>Immunophénotypage</term>
<term>Immunothérapie (effets indésirables)</term>
<term>Lymphocytes T cytotoxiques (immunologie)</term>
<term>Lymphocytes T cytotoxiques (métabolisme)</term>
<term>Lymphocytes T régulateurs (immunologie)</term>
<term>Lymphocytes T régulateurs (métabolisme)</term>
<term>Lymphocytes TIL (immunologie)</term>
<term>Lymphocytes TIL (métabolisme)</term>
<term>Phénotype</term>
<term>Protéine p53 suppresseur de tumeur ()</term>
<term>Protéine p53 suppresseur de tumeur (immunologie)</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Tumeurs de la tête et du cou ()</term>
<term>Tumeurs de la tête et du cou (anatomopathologie)</term>
<term>Tumeurs de la tête et du cou (génétique)</term>
<term>Tumeurs de la tête et du cou (immunologie)</term>
<term>Tumeurs de la tête et du cou (mortalité)</term>
<term>Vaccination</term>
<term>Vaccins anticancéreux (administration et posologie)</term>
<term>Vaccins anticancéreux (effets indésirables)</term>
<term>Vaccins anticancéreux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cancer Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cancer Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Tumor Suppressor Protein p53</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cancer Vaccines</term>
<term>Peptide Fragments</term>
<term>Tumor Suppressor Protein p53</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins anticancéreux</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Immunotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Cytokines</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunothérapie</term>
<term>Vaccins anticancéreux</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Cellules dendritiques</term>
<term>Fragments peptidiques</term>
<term>Lymphocytes T cytotoxiques</term>
<term>Lymphocytes T régulateurs</term>
<term>Lymphocytes TIL</term>
<term>Protéine p53 suppresseur de tumeur</term>
<term>Tumeurs de la tête et du cou</term>
<term>Vaccins anticancéreux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Dendritic Cells</term>
<term>Head and Neck Neoplasms</term>
<term>Lymphocytes, Tumor-Infiltrating</term>
<term>T-Lymphocytes, Cytotoxic</term>
<term>T-Lymphocytes, Regulatory</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dendritic Cells</term>
<term>Lymphocytes, Tumor-Infiltrating</term>
<term>T-Lymphocytes, Cytotoxic</term>
<term>T-Lymphocytes, Regulatory</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Carcinome épidermoïde</term>
<term>Tumeurs de la tête et du cou</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cellules dendritiques</term>
<term>Lymphocytes T cytotoxiques</term>
<term>Lymphocytes T régulateurs</term>
<term>Lymphocytes TIL</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term>
<term>Head and Neck Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Humans</term>
<term>Immunophenotyping</term>
<term>Middle Aged</term>
<term>Neoplasm Staging</term>
<term>Phenotype</term>
<term>Treatment Outcome</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Carcinome épidermoïde</term>
<term>Cellule dendritique</term>
<term>Cellule APC</term>
<term>Gène TP53</term>
<term>Gène suppresseur tumeur</term>
<term>Cancer de la tête et du cou</term>
<term>Gène p53</term>
<term>Humains</term>
<term>Immunophénotypage</term>
<term>Phénotype</term>
<term>Protéine p53 suppresseur de tumeur</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Tumeurs de la tête et du cou</term>
<term>Vaccin peptidique</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against p53 was tested in a phase I clinical trial. Experimental Methods: Monocyte-derived DC from 16 patients were loaded with two modified HLA-class I p53 peptides (Arm 1), additional Th tetanus toxoid peptide (Arm 2), or additional Th wild-type (wt) p53-specific peptide (Arm 3). Vaccine DCs (vDC) were delivered to inguinal lymph nodes at three time points. vDC phenotype, circulating p53-specific T cells, and regulatory T cells (Treg) were serially monitored by flow cytometry and cytokine production by Luminex. vDC properties were compared with those of DC1 generated with an alternative maturation regimen. Results: No grade II-IV adverse events were observed. Two-year disease-free survival of 88% was favorable. p53-specific T-cell frequencies were increased postvaccination in 11 of 16 patients (69%), with IFN-y secretion detected in four of 16 patients. Treg frequencies were consistently decreased (P = 0.006) relative to prevaccination values. The phenotype and function of DC1 were improved relative to vDC. Conclusion: Adjuvant p53-specific vaccination of patients with HNSCC was safe and associated with promising clinical outcome, decreased Treg levels, and modest vaccine-specific immunity. HNSCC patients' DC required stronger maturation stimuli to reverse immune suppression and improve vaccine efficacy.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>États-Unis</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
<li>Pennsylvanie</li>
<li>Texas</li>
</region>
<settlement><li>Pittsburgh</li>
<li>Ulm</li>
</settlement>
<orgName><li>Université d'Ulm</li>
<li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Schuler, Patrick J" sort="Schuler, Patrick J" uniqKey="Schuler P" first="Patrick J." last="Schuler">Patrick J. Schuler</name>
</region>
<name sortKey="Argiris, Athanassios" sort="Argiris, Athanassios" uniqKey="Argiris A" first="Athanassios" last="Argiris">Athanassios Argiris</name>
<name sortKey="Butterfield, Lisa H" sort="Butterfield, Lisa H" uniqKey="Butterfield L" first="Lisa H." last="Butterfield">Lisa H. Butterfield</name>
<name sortKey="Deleo, Albert" sort="Deleo, Albert" uniqKey="Deleo A" first="Albert" last="Deleo">Albert Deleo</name>
<name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<name sortKey="Gooding, William" sort="Gooding, William" uniqKey="Gooding W" first="William" last="Gooding">William Gooding</name>
<name sortKey="Harasymczuk, Malgorzata" sort="Harasymczuk, Malgorzata" uniqKey="Harasymczuk M" first="Malgorzata" last="Harasymczuk">Malgorzata Harasymczuk</name>
<name sortKey="Trivedi, Sumita" sort="Trivedi, Sumita" uniqKey="Trivedi S" first="Sumita" last="Trivedi">Sumita Trivedi</name>
<name sortKey="Trivedi, Sumita" sort="Trivedi, Sumita" uniqKey="Trivedi S" first="Sumita" last="Trivedi">Sumita Trivedi</name>
<name sortKey="Visus, Carmen" sort="Visus, Carmen" uniqKey="Visus C" first="Carmen" last="Visus">Carmen Visus</name>
<name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<name sortKey="Whiteside, Theresa L" sort="Whiteside, Theresa L" uniqKey="Whiteside T" first="Theresa L." last="Whiteside">Theresa L. Whiteside</name>
<name sortKey="Yu Lei" sort="Yu Lei" uniqKey="Yu Lei" last="Yu Lei">YU LEI</name>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Schuler, Patrick J" sort="Schuler, Patrick J" uniqKey="Schuler P" first="Patrick J." last="Schuler">Patrick J. Schuler</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005113 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005113 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:14-0132168
   |texte=   Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

Serveur d'exploration sur Pittsburgh

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.